39 results about "Gram-positive bacteria" patented technology

The invention relates to an antimicrobial peptide consisting of the amino acid sequence: RX1WILX2WLRTWX3X4 wherein X1, X2, X3 and X4 are independently selected from K and R, and wherein each amino acid is independently in the L or D configuration, or a salt or solvate thereof. The use of said antimicrobial peptide in the treatment of an infection caused by Gram negative bacteria, Gram positive bacteria, fungi, and / or yeasts, as well as the use of said peptide as an antimicrobial agent for the prevention of contamination of an article or a living tissue by and / or for the decontamination of an article or a living tissue from Gram negative bacteria, Gram positive bacteria, fungi, and / or yeasts are further aspects of the invention.

The present disclosure relates generally to Gram-positive bacterial strains having enhanced protein productivity phenotypes. Accordingly, certain aspects relate to compositions and methods for constructing recombinant (modified) Gram-positive bacterial strains for enhanced production of proteins of interest.

The bacterial strain Arasana bacillus (CECT 30655) belongs to Gram-positive bacterial flora and bacillus subtilis, and is a stimulant capable of stimulating adaptive metabolism of plants to resist water stress, an improving agent for plant yield and nutrition and an improving agent for polyphenol content. The strain is separated from rhizosphere soil of pinus coast, is cultured on a nutrient agar culture medium (PCA), and is identified as a new strain from the aspects of morphology, biochemistry and genetics for identification through whole genome sequencing. Under a water stress condition, the strain can enhance CO2 fixation and transpiration, optimize photosynthesis energy capture and reduce oxidative stress, so that the strain can be used for increasing yield; as a biological fertilizer, nutrient absorption can be promoted no matter whether water stress exists or not; and the content of antioxidant polyphenols in plant species with medicinal or edible values can also be improved, so that the fruit quality is improved.

The present disclosure provides method of whole genome sequencing of microorganisms such as Gram-positive bacteria, Gram-negative bacteria, viruses, and fungi. The various methods comprising steps of isolating nucleic acid from the microorganism and preparing a library of the isolated nucleic acid. Preferably, the methods of whole genome sequencing described herein are automated to provide a robust and efficient sequencing product for various utilities.

The invention belongs to the technical field of microbial prevention and control of plant diseases and insect pests, and particularly discloses a plant disease biocontrol bacillus cereus strain LCBC246 which is preserved in the China General Microbiological Culture Collection Center (CGMCC), and the preservation number of the strain is CGMCC No.33323. The invention further discloses a preparation method of the plant disease biocontrol bacillus cereus strain LCBC246. The LCBC246 strain provided by the invention is a gram-positive bacterium, has a very strong bacteriostatic effect on colletotrichum fucicola, the bacteriostatic rate is 92.1%, the disease control rate on the colletotrichum fucicola is 90.8%, and the LCBC246 strain has a very good inhibitory effect on other important plateau characteristic crop pathogenic bacteria and also has a remarkable crop growth promoting property. The bacterial inhibition rates of fermentation liquor and volatile substances of the strain LCBC246 on colletotrichum gloeosporioides of macadamia nuts are 62.70% and 76.58% respectively; the bacillus amyloliquefaciens can generate sterilization metabolites such as cellulase, amylase and siderophore, and has a very strong broad-spectrum bacteriostatic effect on various plant pathogenic fungi. Therefore, the strain LCBC246 and the metabolite thereof have the application value of developing bacterial biopesticides.

The invention discloses a bacillus amyloliquefaciens Jcc3 and application thereof in prevention and treatment of aquatic diseases, the classification name of the bacillus amyloliquefaciens Jcc3 is bacillus amyloliquefaciens, the bacillus amyloliquefaciens Jcc3 is preserved in China Center for Type Microbiological Culture Collection, the preservation time is January 25, 2024, and the preservation number is CCTCC NO: M 2024210. The bacillus amyloliquefaciens Jcc3 disclosed by the invention is identified as a gram positive bacterium. The strain can produce lipopeptides, proteins and other substances with bacteriostatic action, and has a significant inhibitory effect on aquatic disease aeromonas veronii. By inhibiting the growth and reproduction of the aeromonas veronii, aquatic diseases caused by the aeromonas veronii can be effectively prevented and controlled, so that the immunity of aquatic animals is enhanced, and the death rate of the aquatic animals is reduced. In conclusion, the bacillus amyloliquefaciens Jcc3 has great application potential in prevention and control of aquatic diseases, especially in prevention and control of diseases caused by aeromonas veronii.

An optimized protein-free tripartite vaccine protects against lethal blood and lung infections caused by a variety of nosocomial pathogens across taxonomic kingdoms, including Gram- positive bacteria, Gram-negative bacteria, and fungi is provided as well as method for using same.

The present invention contemplates a topical ophthalmic system for treating a Gram-positive bacterially-infected mammalian eye. The system comprises an ophthalmic composition containing a halogenated fluorescein or a pharmaceutically acceptable salt or ester thereof dissolved or dispersed in an aqueous ophthalmic carrier and present in an anti-bacterial keratitis-treating effective concentration of about 0.2 μg / mL to about 50 μg / mL. The ophthalmic composition has a pH value of about 6.5 to about 7.6, a viscosity of about 10 to about 300 cps and an osmolality of about 270 mOsm / kg to about 340 mOsm / kg. The ophthalmic composition is present in a vessel opaque to actinic light. Also contemplated is a method of treating a mammal having a Gram-positive bacterial infection of an eye by administering the ophthalmic composition to the infected eye and maintaining the treated eye in the substantial absence of actinic light for about 3 hours to about 12 hours.

Embodiments relate to a composition comprising a bacteriophage or a mutant thereof and a storage solution, wherein the bacteriophage or the mutant thereof is capable of killing a Gram-positive bacterium comprising Staphylococcus aureus, wherein the composition is stable for at least about a year at 39.2-46.4° F. (4-8° C.).

The invention discloses bacillus velezensis Jcl-10 and application of the bacillus velezensis Jcl-10 in prevention and treatment of vibrio cholerae. The strain Jcl-10 is preserved in the China Center for Type Culture Collection, the preservation time is January 25, 2024, and the preservation number is CCTCC N: M 2024212. The bacillus velezensis Jcl-10 disclosed by the invention is identified as a gram positive bacterium after being subjected to gram staining. The bacterial strain can produce antibacterial peptide substances, antibacterial protein substances, polyketide synthetase substances and the like with bacteriostatic action, and can be well applied to prevention and treatment of aquatic diseases caused by vibrio cholerae. The Jcl-10 is added into the aquatic feed, so that the morbidity of aquaculture animals can be effectively reduced, and the economic yield of the aquaculture animals can be increased. In conclusion, the bacillus velezensis Jcl-10 disclosed by the invention has outstanding performance in the prevention and treatment of vibrio cholerae, and provides a powerful guarantee for continuous and healthy culture of aquatic products.

The photosensitive compound comprises a beta-lactam ring as shown in a formula I and a Ce6 photosensitizer, and does not contain a quenching group. When the compound is in contact with MRSA and other gram positive bacteria, the beta-lactam ring structure in the compound is combined with MRSA and other gram positive bacteria cell wall synthesis key enzyme-transpeptidase to provide targeting for the photosensitizer Ce6, so that the targeting effect on the bacteria is realized, the specificity is strong, a large amount of active oxygen is generated under illumination to kill the bacteria, and the compound can be used as a photosensitizer Ce6. Meanwhile, damage to normal tissues is avoided, photodynamic therapy on bacterial infection is facilitated, and the photodynamic therapy has high efficiency and low tissue toxicity.

The invention provides a TB derivative with photodynamic antibacterial and anti-tumor activity and a synthesis method thereof, the derivative comprises a carbazole-TB-thiophene-pyridinium derivative, the structural formula of the derivative is shown in the specification, and the four derivatives have good viscosity response and aggregation-induced emission property and can efficiently and synchronously generate I-type and II-type active oxygen. The TB-CB-1, the TB-TPA-1 and the TB-TPA-2 have good photodynamic antibacterial activity on tested gram positive bacteria (G + bacteria), and the antibacterial rates of the TB-CB-1, the TB-TPA-1 and the TB-TPA-2 on the three kinds of G + bacteria are all larger than 90% when the concentration of the TB-CB-1, the TB-TPA-1 and the TB-TPA-2 is 2 mol. L <-1 >. The four compounds have strong photodynamic anti-tumor activity and large light and dark toxicity difference, the IC50 values of the TB-CB-1 to MCF-7, A549 and HepG2 cells are all greater than 100 [mu] g.mL <-1 > in the absence of illumination, and the IC50 values are respectively reduced to 1.53 [mu] g.mL <-1 > and 0.28 [mu] g.mL <-1 > under illumination; the IC50 of the TB-TPA-2 to A549 cells under a dark condition is greater than 200 [mu] g.mL <-1 >, and the illumination is reduced to 2.01 [mu] g.mL <-1 >. The invention provides a new thought for design and synthesis of a novel photodynamic antibacterial / antitumor photosensitizer.

The present disclosure is generally related to Gram-positive bacterial strains comprising enhanced protein productivity phenotypes. Certain aspects are therefore related to compositions and methods for constructing recombinant (modified) Gram-positive bacterial strains for the enhanced production of proteins of interest.

Provided herein is an antimicrobial composition for hygiene applications. The antimicrobial composition comprises an effective concentration of a cathelicidin LL-37 peptide fragment in combination with an effective concentration of non- ionic surfactant. The non-ionic surfactant is an Alkyl-Poly Glucoside (APG) or alcohol ethoxylates or both. The antimicrobial composition further comprises of a chelating agent like disodium EDTA, or malic acid or citric acid or GLDA or PES A. The composition achieves log reduction of at least 3 against Gram negative bacteria Pseudomonas aeruginosa, Escherichia coll and Gram positive bacteria Staphylococcus aureus, Enterococcus hirae.

The present invention contemplates a topical ophthalmic system for treating a Gram-positive bacterially-infected mammalian eye. The system comprises an ophthalmic composition containing a halogenated fluorescein or a pharmaceutically acceptable salt or ester thereof dissolved or dispersed in an aqueous ophthalmic carrier and present in an anti-bacterial keratitis-treating effective concentration of about 0.2 μg / mL to about 50 μg / mL. The ophthalmic composition has a pH value of about 6.5 to about 7.6, a viscosity of about 10 to about 300 cps and an osmolality of about 270 mOsm / kg to about 340 mOsm / kg. The ophthalmic composition is present in a vessel opaque to actinic light. Also contemplated is a method of treating a mammal having a Gram-positive bacterial infection of an eye by administering the ophthalmic composition to the infected eye and maintaining the treated eye in the substantial absence of actinic light for about 3 hours to about 12 hours.

The application discloses an alkyl pyridine salt type aggregation-induced emission compound, a preparation method and application thereof, a molecular structural formula of the alkyl pyridine salt type aggregation-induced emission compound is as follows: the preparation method comprises the following steps: stirring and refluxing raw material D, 1,4-dimethyl pyridine-1-iodide, anhydrous ethanol and piperidine overnight, after the reaction mixture is cooled, vacuum concentration is carried out, and the crude product is purified by elution, so that the alkyl pyridine salt type aggregation-induced emission compound is obtained. The alkyl pyridine salt type aggregation-induced emission compound provided by the application can simultaneously and efficiently kill gram-positive bacteria and gram-negative bacteria.

The present invention relates to an inhalable pharmaceutical composition comprising clofazimine, or a pharmaceutically acceptable derivative of clofazimine, a clofazimine salt or a polymorph of clofazimine, or combination thereof, and a pharmaceutically acceptable carrier and / or excipient for use in the treatment or prophylaxis of a nontuberculous bacterial infection of the lungs, wherein clofazimine is in an amount of 1 mg to 20 mg wt % in the composition, and wherein the inhalable pharmaceutical composition is provided by inhalation in an effective daily dose of up to 90 mg of clofazimine. There is also provided pharmaceutical combinations comprising clofazimine in the form of an aerosol for pulmonary inhalation for administration alone, or concomitantly with other drugs as combination therapy in the treatment and / or prophylaxis of pulmonary infections caused by mycobacteria and other gram-positive bacteria, and of pulmonary fungal infections.

The invention is directed to an aqueous extract of Eruca sativa (arugula) leaves that has antimicrobial activity on Gram-positive bacteria and mycoplasmas. The extract may be purified away from solid or insoluble components, standardized based on the weight of its non-aqueous or solid content, assayed for antimicrobial activity, and provided in an aseptic or sterile form for pharmaceutical use. It may be used to kill or inhibit the growth of microorganisms such as Gram positive bacteria, promote wound healing, or as prophylaxis against host colonization or infection by a microorganism.

The invention relates to a soluble expression mussel mucin polypeptide and a preparation method and application thereof, the soluble expression mussel mucin polypeptide is at least one of MAP-PEP1 and MAP-PEP2, the amino acid sequence of the MAP-PEP1 is as shown in SEQ ID NO.1, and the amino acid sequence of the MAP-PEP2 is as shown in SEQ ID NO.2. The invention further discloses a preparation method of the soluble expression mussel mucin polypeptide. The prepared mussel mucin polypeptides MAP-PEP1 and MAP-PEP2 rich in positive charges and DOPA groups can effectively destroy cell membranes of gram positive bacteria and gram negative bacteria, induce an oxidative stress reaction and inhibit bacterial proliferation; the material can be used for preparing a multifunctional biological active material, can also promote cell adhesion, migration and proliferation, is beneficial to wound healing, has a certain effect in the aspect of free radical scavenging, has great potential to become a next-generation multifunctional biological active material, and provides a theoretical basis for wide application in the fields of wound nursing, implant materials, drug delivery, cosmetics and the like.

The technical field relates to methods for promoting gut microbiome health using low G+C Directed (LDN) analogs. More particularly, the technical field relates to methods of using LDN analogs as inhibitors of DNA Polymerase IIIC (DNA pol IIIC) enzyme to selectively reduce physiologically harmful Gram-positive bacteria with a genome having low amounts of Guanine and Cytosine (rather the genomes comprise a greater amount of adenine and thymine / uracil nucleotides) in the gut microbiome while simultaneously maintaining or increasing the proportions of beneficial microflora.

The present invention relates to photoactive compounds and compositions comprising the same, and their use in the treatment and prevention of infections caused by Gram-positive bacteria. In embodiments, the present invention relates to methods of administering compounds and compositions, and particularly topical compositions, for the treatment and prevention of bacterial infections caused by Gram-positive bacteria, including diseases and conditions caused by Gram-positive bacteria, as well as infections of skin lesions.

Provided herein are probiotic compositions and methods for treating animals or humans, or human or animal feed, or a surface in contact therewith comprising: feeding or providing a feed, supplement, additive, or food to animals or humans with a composition comprising one or more probiotic bacteria, supernatant, extract, broth, or fermentate thereof, selected from L28, L3AL3 A, L20-B, J7, J14, J27, J43, J16, J34, J25, L5-A and J19 provided in an amount sufficient to be at least one of: bactericidal against bacteria selected from at least one of: spore-forming bacteria, gram positive bacteria, gram negative bacteria, or combinations thereof, in animal or human intestines, improve gut structure, reduce gut inflammation, improved nutrient digestibility, improve mineral absorption and growth performance, reduce carriage, reduce fecal shedding, or reduce gut infection and inflammation.

The present invention discloses novel nigericin derivatives of general formula (I) that exhibit low toxicity and inhibition activity against gram-positive bacteria, gram-negative bacteria, and viruses. The present invention also discloses a process for preparation of the compound of the general formula (I). Further, the present invention provides pharmaceutical compositions comprising the compound of general formula (I) and methods to treat bacterial and viral infections.

The invention belongs to the technical field of polypeptide preparation, and provides collagen-based antibacterial peptide and a preparation method thereof. Connecting carboxyl of the collagen peptide with amino acid, dipeptide or tripeptide; the amino acid, the dipeptide or the tripeptide is composed of lysine and arginine. The antibacterial peptide can be used as an effective component of an antibacterial drug and can be prepared into an external application patch, a suppository, a surgical implant material and the like for preventing bacterial and fungal infection. The antibacterial peptide can also be used as a feed additive or a veterinary drug to be applied to animals. The raw materials are wide in source, the synthesis method is simple, and the cost is low; the prepared antibacterial peptide is good in salt tolerance, has an antibacterial effect under a wide pH range, and is good in biological safety; the antibacterial peptide has a good inhibition effect on gram-negative and gram-positive bacteria, especially has good biological activity on common vaginal malignant bacteria, and has a wide application prospect.

The present disclosure relates to novel lantibiotics, lantibiotic pharmaceutical compositions, isolated and recombinant lantibiotic-producing bacteria, bacterial pharmaceutical compositions, methods of producing novel lantibiotics from lantibiotic-producing bacteria, and methods of using such lantibiotics, lantibiotic pharmaceutical compositions, and bacterial pharmaceutical compositions to treat gram-positive bacteria infections, including vancomycin resistant enterococci infections, in patients, and to treat food and other objects to avoid gram-positive bacteria contamination.

An optimized protein-free tripartite vaccine protects against lethal blood and lung infections caused by a variety of nosocomial pathogens across taxonomic kingdoms, including Gram- positive bacteria, Gram-negative bacteria, and fungi is provided as well as method for using same.

The present invention relates to an antimicrobial composition that not only cleans hard and soft inanimate surfaces, but also provides antimicrobial efficacy against both gram-positive and gram-negative bacteria. This is achieved by a combination of a rhamnolipid surfactant, an amino acid surfactant and a selected chelating agent.

The present invention relates to four types of Gram-positive bacteria (Brevibacterium frigoritolerans (HRS1, KCTC 14301BP), Bacillus niacini (HRS2, KCTC 14302BP), Solibacillus silvestris (HRS3, KCTC 14303BP), and Bacillus luciferensis (HRS4, KCTC 14304BP) strains), which increase resistance of plants against plant pathogens and to a composition of a biocontrol agent by using same and, more specifically, to a microbial fertilizer having a control effect against microbial diseases such as bacterial wilt occurring in crops (tomatoes, peppers, etc.), and against pests such as aphids by using the strains alone or a mixture thereof.

Provided is a technology for improving the flavor of food products. The flavor of food products is improved by the following ingredients (A): (A) Lysozyme-treated product of cell walls of gram-positive bacterium.

Disclosed is the use of copper ionophores for overcoming or inhibiting the development of resistance of a gram-positive bacterium to an antibiotic. More particularly, this disclosure relates to the use of a thiosemicarbazone, elesclomol or nitroxoline or a pharmaceutically acceptable salt or solvate thereof for conferring antibiotic sensitivity to a resistant gram-positive bacterium, inhibiting the development of resistance of a gram-positive bacterium to an antibiotic, increasing the susceptibility of a gram-positive bacterium to an antibiotic and / or treating or inhibiting the development of a gram-positive bacterial infection in a subject. Also provided is the use of a thiosemicarbazone, elesclomol or nitroxoline or a pharmaceutically acceptable salt or solvate thereof as an antibiotic adjuvant or potentiator.